These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 7374415)

  • 1. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
    Steger W
    Fortschr Med; 1980 May; 98(18):(718-20). PubMed ID: 7390386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H
    Med Klin; 1979 Jun; 74(22):875-6. PubMed ID: 470785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clofibrate therapy--the status quo].
    Reuter W
    Z Gesamte Inn Med; 1982 Jan; 37(2):59-63. PubMed ID: 7080553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F; López IM; Jover E
    J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hyperlipoproteinemia type II with etofibrate.
    Gustafson A
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):498-502. PubMed ID: 528096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
    Schwartzkopff W; Schilling A
    Med Welt; 1980 Dec; 31(50):1845-50. PubMed ID: 7464535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.